Compare Aurora Cannabis Inc (ACB) vs iShares Core Growth Allocation ETF (AOR) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

AOR, the iShares Core Growth Allocation ETF, trades at $70.12, up 0.57% on the day, with a bullish technical signal driven by moving averages. The ETF maintains a fixed 60/40 stock/bond allocation, rebalances semiannually, and offers low-cost exposure with a 0.20% fee. Recent news highlights its role as a core holding but notes long-term underperformance versus the S&P 500 over the past decade.

The outlook for AOR hinges on its diversified asset allocation strategy providing stability, though it faces risks from equity and fixed income market volatility. Its simplicity appeals to investors seeking a hands-off approach, but competition from pure equity funds and interest rate sensitivity are key considerations for potential returns.